688739 成大生物
已收盘 09-18 15:00:01
资讯
新帖
简况
成大生物（本溪）取得适用于超滤系统气密性检测装置专利，减少漏气风险
金融界 · 08-30
成大生物（本溪）取得适用于超滤系统气密性检测装置专利，减少漏气风险
成大生物（688739）2025年中报简析：净利润同比下降44.47%
证券之星 · 08-29
成大生物（688739）2025年中报简析：净利润同比下降44.47%
图解成大生物中报：第二季度单季净利润同比下降63.91%
证券之星 · 08-28
图解成大生物中报：第二季度单季净利润同比下降63.91%
成大生物：2025年上半年净利润1.22亿元，同比下降44.47%
金融界 · 08-28
成大生物：2025年上半年净利润1.22亿元，同比下降44.47%
每周股票复盘：成大生物（688739）取消监事会并修订公司章程
证券之星 · 08-16
每周股票复盘：成大生物（688739）取消监事会并修订公司章程
生物制品行业盘中跳水，成大生物跌0.35%
市场透视 · 08-12
生物制品行业盘中跳水，成大生物跌0.35%
每周股票复盘：成大生物（688739）计划回购股份1000万至2000万元
证券之星 · 08-09
每周股票复盘：成大生物（688739）计划回购股份1000万至2000万元
成大生物：尚未实施本次股份回购计划
格隆汇 · 08-04
成大生物：尚未实施本次股份回购计划
生物制品行业点评报告-减重赛道全球前沿进展跟踪(一)：AMYLIN布局正当时
开源证券 · 08-03
生物制品行业点评报告-减重赛道全球前沿进展跟踪(一)：AMYLIN布局正当时
每周股票复盘：成大生物（688739）变更董事会秘书
证券之星 · 08-02
每周股票复盘：成大生物（688739）变更董事会秘书
成大生物中标巫山县疫苗采购项目 巩固疫苗领域市场地位
自选股中标信息 · 07-31
成大生物中标巫山县疫苗采购项目 巩固疫苗领域市场地位
成大生物：33岁投行派李业基接棒董秘，能否破解疫苗龙头价格腰斩、净利连降困局？
新浪证券 · 07-31
成大生物：33岁投行派李业基接棒董秘，能否破解疫苗龙头价格腰斩、净利连降困局？
生物制品行业深度报告：多发性硬化 百亿美金市场 BTKI发展前景广阔
开源证券 · 07-29
生物制品行业深度报告：多发性硬化 百亿美金市场 BTKI发展前景广阔
成大生物：崔建伟辞任董秘职务 李业基接任
财中社 · 07-29
成大生物：崔建伟辞任董秘职务 李业基接任
成大生物收盘上涨2.15%，滚动市盈率35.58倍，总市值118.69亿元
金融界 · 07-24
成大生物收盘上涨2.15%，滚动市盈率35.58倍，总市值118.69亿元
成大生物中标非免疫规划疫苗项目 有望提升公司疫苗业务收入
自选股中标信息 · 07-24
成大生物中标非免疫规划疫苗项目 有望提升公司疫苗业务收入
生物制品行业盘中跳水，成大生物跌0.14%
市场透视 · 07-23
生物制品行业盘中跳水，成大生物跌0.14%
成大生物中标非免疫规划疫苗项目 增强疫苗业务市场竞争力
自选股中标信息 · 07-19
成大生物中标非免疫规划疫苗项目 增强疫苗业务市场竞争力
成大生物涨5.03%创近4个月新高 产品结构优化与估值修复预期驱动
智选洞察 · 07-14
成大生物涨5.03%创近4个月新高 产品结构优化与估值修复预期驱动
成大生物获得实用新型专利授权：“一种连续流超声破碎装置”
证券之星企业动态 · 07-04
成大生物获得实用新型专利授权：“一种连续流超声破碎装置”
加载更多
公司概况
公司名称：
辽宁成大生物股份有限公司
所属行业：
医药制造业
上市日期：
2021-10-28
主营业务：
辽宁成大生物股份有限公司的主营业务是人用疫苗的研发、生产与销售。公司的主要产品是人用狂犬病疫苗和人用乙脑灭活疫苗。
发行价格：
110.00
{"stockData":{"symbol":"688739","market":"SH","secType":"STK","nameCN":"成大生物","latestPrice":27.17,"timestamp":1758178801000,"preClose":27.51,"halted":0,"volume":2304946,"delay":0,"changeRate":-0.0124,"floatShares":416000000,"shares":416000000,"eps":0.5881,"marketStatus":"已收盘","change":-0.34,"latestTime":"09-18 15:00:01","open":27.49,"high":27.67,"low":27.1,"amount":63267300,"amplitude":0.0207,"askPrice":27.18,"askSize":100,"bidPrice":27.17,"bidSize":35,"shortable":0,"etf":0,"ttmEps":0.5881,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1758245400000},"marketStatusCode":5,"adr":0,"adjPreClose":27.51,"symbolType":"stock_kcb","openAndCloseTimeList":[[1758159000000,1758166200000],[1758171600000,1758178800000]],"highLimit":30.26,"lowLimit":24.76,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":416450000,"isCdr":false,"pbRate":1.21,"roa":"--","peRate":46.199626,"roe":"1.28%","epsLYR":0.83,"committee":-0.355164,"marketValue":11315000000,"turnoverRate":0.0055,"status":1,"afterMarket":{"amount":0,"volume":0,"close":27.17,"buyVolume":0,"sellVolume":0,"time":1758180839260,"indexStatus":"已收盘 09-18 15:30:00","preClose":27.51},"floatMarketCap":11315000000},"requestUrl":"/m/hq/s/688739","defaultTab":"news","newsList":[{"id":"2563100524","title":"成大生物（本溪）取得适用于超滤系统气密性检测装置专利，减少漏气风险","url":"https://stock-news.laohu8.com/highlight/detail?id=2563100524","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563100524?lang=zh_cn&edition=full","pubTime":"2025-08-30 09:03","pubTimestamp":1756515831,"startTime":"0","endTime":"0","summary":"国家知识产权局信息显示，成大生物（本溪）有限公司取得一项名为“一种适用于超滤系统气密性检测装置”的专利，授权公告号CN 223272095 U，申请日期为2024年11月。天眼查资料显示，成大生物（本溪）有限公司，成立于2021年，位于本溪市，是一家以从事医药制造业为主的企业。通过天眼查大数据分析，成大生物（本溪）有限公司参与招投标项目21次，专利信息32条，此外企业还拥有行政许可267个。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/08/30090352823694.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0239","688739"],"gpt_icon":0},{"id":"2563070638","title":"成大生物（688739）2025年中报简析：净利润同比下降44.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2563070638","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563070638?lang=zh_cn&edition=full","pubTime":"2025-08-30 06:19","pubTimestamp":1756505986,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期成大生物发布2025年中报。根据财报显示，成大生物净利润同比下降44.47%。截至本报告期末，公司营业总收入7.07亿元，同比下降19.75%，归母净利润1.22亿元，同比下降44.47%。按单季度数据看，第二季度营业总收入3.48亿元，同比下降32.48%，第二季度归母净利润5007.67万元，同比下降63.91%。然而去年的净利率为20.45%，算上全部成本后，公司产品或服务的附加值高。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025083000010737.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688739"],"gpt_icon":0},{"id":"2563050228","title":"图解成大生物中报：第二季度单季净利润同比下降63.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2563050228","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563050228?lang=zh_cn&edition=full","pubTime":"2025-08-29 01:49","pubTimestamp":1756403397,"startTime":"0","endTime":"0","summary":"证券之星消息，成大生物2025年中报显示，公司主营收入7.07亿元，同比下降19.75%；归母净利润1.22亿元，同比下降44.47%；扣非净利润1.02亿元，同比下降51.6%；其中2025年第二季度，公司单季度主营收入3.48亿元，同比下降32.48%；单季度归母净利润5007.67万元，同比下降63.91%；单季度扣非净利润3941.21万元，同比下降72.31%；负债率4.41%，投资收益1326.7万元，财务费用-2163.43万元，毛利率79.1%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082900000646.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688739"],"gpt_icon":0},{"id":"2562653036","title":"成大生物：2025年上半年净利润1.22亿元，同比下降44.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562653036","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562653036?lang=zh_cn&edition=full","pubTime":"2025-08-28 19:11","pubTimestamp":1756379483,"startTime":"0","endTime":"0","summary":"成大生物公告，2025年上半年营业收入7.07亿元，同比下降19.75%。净利润1.22亿元，同比下降44.47%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/08/28191152783771.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["688739"],"gpt_icon":0},{"id":"2560592570","title":"每周股票复盘：成大生物（688739）取消监事会并修订公司章程","url":"https://stock-news.laohu8.com/highlight/detail?id=2560592570","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560592570?lang=zh_cn&edition=full","pubTime":"2025-08-17 04:20","pubTimestamp":1755375617,"startTime":"0","endTime":"0","summary":"截至2025年8月15日收盘，成大生物报收于29.02元，较上周的28.69元上涨1.15%。本周关注点公司公告汇总：成大生物取消监事会并修订公司章程，相关议案将提交股东会审议。辽宁成大生物股份有限公司将于2025年8月28日9点30分召开2025年第一次临时股东会，审议取消监事会、废止《监事会议事规则》并修订《公司章程》及其附件，制定公司董事和高级管理人员薪酬管理制度，选举徐飚先生和周岳先生为第五届董事会非独立董事。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025081700000660.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688739","BK0239"],"gpt_icon":0},{"id":"2558455697","title":"生物制品行业盘中跳水，成大生物跌0.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2558455697","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558455697?lang=zh_cn&edition=full","pubTime":"2025-08-12 10:40","pubTimestamp":1754966408,"startTime":"0","endTime":"0","summary":"08月12日，生物制品行业盘中跳水，截至10点40分，生物制品行业整体指数下跌1.01%，报6884.300点。从个股上来看，该行业的成分股中，成大生物跌0.35%，长春高新、万泰生物、上海莱士跌幅居前。从资金上来看，截止发稿，生物制品行业主力净流入为-3.27亿，其中西藏药业受到资金热捧，主力净流入2.03亿；拉长时间线来看，该板块近20日主力资金净流入-45.53亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025081210400897420a71&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025081210400897420a71&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600211","603392","BK0239","688739"],"gpt_icon":0},{"id":"2558507232","title":"每周股票复盘：成大生物（688739）计划回购股份1000万至2000万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2558507232","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558507232?lang=zh_cn&edition=full","pubTime":"2025-08-10 03:04","pubTimestamp":1754766256,"startTime":"0","endTime":"0","summary":"本周关注点成大生物计划以集中竞价交易方式回购股份，金额为1000万元至2000万元公司公告汇总成大生物计划以集中竞价交易方式回购股份，回购方案首次披露日为2025年6月19日，实施期限为2025年6月19日至2026年6月18日。预计回购金额为1000万元至2000万元，回购用途为用于员工持股计划或股权激励。公司将根据回购股份事项进展情况及时履行信息披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025081000000529.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688739","BK0239"],"gpt_icon":0},{"id":"2556633801","title":"成大生物：尚未实施本次股份回购计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2556633801","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556633801?lang=zh_cn&edition=full","pubTime":"2025-08-04 15:33","pubTimestamp":1754292810,"startTime":"0","endTime":"0","summary":"格隆汇8月4日丨成大生物(688739.SH)公布，截至2025年7月31日，公司尚未实施本次股份回购计划，公司后续将根据市场情况择机实施本次回购计划。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080415333894ce32d1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080415333894ce32d1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688739"],"gpt_icon":0},{"id":"2556879631","title":"生物制品行业点评报告-减重赛道全球前沿进展跟踪(一)：AMYLIN布局正当时","url":"https://stock-news.laohu8.com/highlight/detail?id=2556879631","media":"开源证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556879631?lang=zh_cn&edition=full","pubTime":"2025-08-04 00:00","pubTimestamp":1754236800,"startTime":"0","endTime":"0","summary":"近期重磅BD 交易总结艾伯维和罗氏先后在2025 年一季度花重金布局amylin 分子。艾伯维将支付首付款3.5 亿美金，里程碑高达18.75 亿美金，以及销售分成。高质量减重方面，临床前DIO 大鼠数据显示Eloralintide 减少的体重最高达91%为脂肪。而目前GLP-1 类药物减重中约20%-40%为瘦体重。此外，礼来在ADA 大会上表示未来不排除eloralintide 开发月度制剂的可能性。Metsera 公司明确MET-223i 将定位为月度制剂。值得指出的是，Structure 和众生药业以小分子形式切入了amylin 赛道。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250804093615a4733c3b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250804093615a4733c3b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688336","688739","603087","688276","600739","600867","688105","688319","688443","688687","BK0239","600211","600161","688137","688488","603392","688163","688670","688177","688520","688166","688278","688293","603590"],"gpt_icon":0},{"id":"2556296738","title":"每周股票复盘：成大生物（688739）变更董事会秘书","url":"https://stock-news.laohu8.com/highlight/detail?id=2556296738","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556296738?lang=zh_cn&edition=full","pubTime":"2025-08-03 04:03","pubTimestamp":1754164990,"startTime":"0","endTime":"0","summary":"截至2025年8月1日收盘，成大生物报收于28.39元，较上周的28.52元下跌0.46%。本周关注点成大生物变更董事会秘书，李业基先生接任公司公告汇总辽宁成大生物股份有限公司宣布崔建伟先生因工作职责调整不再担任公司董事会秘书职务，离任时间为2025年7月，但仍继续担任公司董事、副总经理及财务总监职务。公司对崔建伟先生担任董事会秘书期间为公司发展所做出的贡献表示感谢。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025080300000706.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688739","BK0239"],"gpt_icon":0},{"id":"2555829448","title":"成大生物中标巫山县疫苗采购项目 巩固疫苗领域市场地位","url":"https://stock-news.laohu8.com/highlight/detail?id=2555829448","media":"自选股中标信息","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555829448?lang=zh_cn&edition=full","pubTime":"2025-07-31 19:14","pubTimestamp":1753960458,"startTime":"0","endTime":"0","summary":"2025年07月31日，据天眼查数据，重庆市巫山县非免疫规划疫苗采购目录（2025年）显示，中标方为成大生物（sh688739），招标方为重庆市巫山县疾病预防控制中心。成大生物主营业务涵盖人用狂犬病疫苗（占比约91.72%），人用乙脑灭活疫苗（占比约8.28%）。截至发稿，成大生物股价报28.28元，下跌0.81%，成交额至9403.15万元（5日均值8571.38万元）。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。中标数据由天眼查提供，由程序或算法识别中标信息页面生成，可能与实际存在差异，不作为决策依据。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731191419a6cb8f01&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731191419a6cb8f01&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688739","159646","BK0239"],"gpt_icon":0},{"id":"2555003727","title":"成大生物：33岁投行派李业基接棒董秘，能否破解疫苗龙头价格腰斩、净利连降困局？","url":"https://stock-news.laohu8.com/highlight/detail?id=2555003727","media":"新浪证券","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555003727?lang=zh_cn&edition=full","pubTime":"2025-07-31 13:55","pubTimestamp":1753941317,"startTime":"0","endTime":"0","summary":"更引人注目的是，他今年5月才入职成大生物，仅两个月便执掌董秘要职，这种“空降”速度在上市公司中颇为罕见。2024年年报显示，人用狂犬病疫苗的毛利率下滑至82.21%。截至7月30日收盘，成大生物股价报28.51元，市值118.98亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025073113555597295d0c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025073113555597295d0c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["159645","BK0239","688739"],"gpt_icon":0},{"id":"2555369099","title":"生物制品行业深度报告：多发性硬化 百亿美金市场 BTKI发展前景广阔","url":"https://stock-news.laohu8.com/highlight/detail?id=2555369099","media":"开源证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555369099?lang=zh_cn&edition=full","pubTime":"2025-07-30 00:00","pubTimestamp":1753804800,"startTime":"0","endTime":"0","summary":"MS 地理分布呈现鲜明的“纬度梯度”现象，高纬度地区发病率较高；根据Frost & Sullivan数据，全球与中国多发性硬化存量患者数量预计将在2030 年达到371/6 万人。BTK 抑制剂有望填补PMS 领域治疗空白，2025H2 数据催化密集BTK 抑制剂具有较好的血脑屏障穿透性，可通过调控B 细胞和小胶质细胞等关键免疫细胞，分别抑制炎症反应和神经退行性进程，为PMS 提供了潜在有效的治疗手段。投资建议MS 全球存量患者基数较大，存量产品市场规模约200 亿美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250730111622a6c8dd18&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250730111622a6c8dd18&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688488","BK0196","688428","BK0012","688163","LU1997245177.USD","600739","LU0405327148.USD","LU1997244956.HKD","LU2580892862.HKD","688319","LU1655091616.SGD","LU1969619763.USD","600161","09969","600276","LU1064130708.USD","03692","688336","LU1064131003.USD","688136","688739","BK0060","BK0028","LU1328615791.USD","688276","600211","LU1997245094.SGD","BK0188","LU2328871848.SGD","688670","01952","LU2488822045.USD","BK0239","688235","01276","688105","BK0183","LU0405327494.USD","603392","LU2148510915.USD","LU2495084118.USD","LU2580892789.USD"],"gpt_icon":0},{"id":"2555063037","title":"成大生物：崔建伟辞任董秘职务 李业基接任","url":"https://stock-news.laohu8.com/highlight/detail?id=2555063037","media":"财中社","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555063037?lang=zh_cn&edition=full","pubTime":"2025-07-29 18:36","pubTimestamp":1753785391,"startTime":"0","endTime":"0","summary":"7月29日，成大生物（688739）发布公告，崔建伟因工作职责调整原因，不再担任公司董事会秘书职务，仍继续担任公司董事、副总经理及财务总监职务。公司于2025年7月29日召开董事会会议，同意聘任李业基为公司董事会秘书。2025年一季度，成大生物实现收入3.58亿元，归母净利润7222万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072918370697253934&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072918370697253934&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688739"],"gpt_icon":0},{"id":"2553207702","title":"成大生物收盘上涨2.15%，滚动市盈率35.58倍，总市值118.69亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2553207702","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553207702?lang=zh_cn&edition=full","pubTime":"2025-07-24 19:56","pubTimestamp":1753358162,"startTime":"0","endTime":"0","summary":"7月24日，成大生物今日收盘28.5元，上涨2.15%，滚动市盈率PE达到35.58倍，创101天以来新低，总市值118.69亿元。从行业市盈率排名来看，公司所处的生物制品行业市盈率平均85.49倍，行业中值45.48倍，成大生物排名第42位。股东方面，截至2025年3月31日，成大生物股东户数25451户，较上次减少564户，户均持股市值35.28万元，户均持股数量2.76万股。最新一期业绩显示，2025年一季报，公司实现营业收入3.58亿元，同比-1.73%；净利润7221.80万元，同比-11.35%，销售毛利率75.88%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/07/24195651957306.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["688739","BK0239"],"gpt_icon":0},{"id":"2553306207","title":"成大生物中标非免疫规划疫苗项目 有望提升公司疫苗业务收入","url":"https://stock-news.laohu8.com/highlight/detail?id=2553306207","media":"自选股中标信息","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553306207?lang=zh_cn&edition=full","pubTime":"2025-07-24 19:33","pubTimestamp":1753356795,"startTime":"0","endTime":"0","summary":"2025年07月24日，据天眼查数据，重庆市奉节县疾病预防控制中心关于2025年非免疫规划疫苗遴选结果的公示显示，中标方为成大生物，招标方为重庆市奉节县疾病预防控制中心。成大生物主营业务涵盖人用狂犬病疫苗，人用乙脑灭活疫苗。截至发稿，成大生物股价报28.5元，上涨2.15%，成交额至1.15亿元。股市有风险，请谨慎决策。中标数据由天眼查提供，由程序或算法识别中标信息页面生成，可能与实际存在差异，不作为决策依据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724193318a4613b45&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724193318a4613b45&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["159646","BK0239","688739"],"gpt_icon":0},{"id":"2553291786","title":"生物制品行业盘中跳水，成大生物跌0.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2553291786","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553291786?lang=zh_cn&edition=full","pubTime":"2025-07-23 14:39","pubTimestamp":1753252778,"startTime":"0","endTime":"0","summary":"07月23日，生物制品行业盘中跳水，截至14点39分，生物制品行业整体指数下跌1.01%，报6583.980点。从个股上来看，该行业的成分股中，成大生物跌0.14%，跌幅居前。从资金上来看，截止发稿，生物制品行业主力净流入为-5.10亿，其中沃森生物受到资金热捧，主力净流入4334.22万；拉长时间线来看，该板块近20日主力资金净流入-25.17亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072314393897b1eba9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072314393897b1eba9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688739","BK0239"],"gpt_icon":0},{"id":"2552411072","title":"成大生物中标非免疫规划疫苗项目 增强疫苗业务市场竞争力","url":"https://stock-news.laohu8.com/highlight/detail?id=2552411072","media":"自选股中标信息","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552411072?lang=zh_cn&edition=full","pubTime":"2025-07-19 19:19","pubTimestamp":1752923997,"startTime":"0","endTime":"0","summary":"2025年07月19日，据天眼查数据，四川省攀枝花市仁和区2025-2026年度非免疫规划疫苗遴选结果公示显示，中标方为成大生物，招标方为攀枝花市仁和区疾病预防控制中心,攀枝花市仁和区疾控中心。成大生物主营业务涵盖人用狂犬病疫苗，人用乙脑灭活疫苗。截至发稿，成大生物股价报27.82元，上涨0.07%，成交额至5707.63万元。股市有风险，请谨慎决策。中标数据由天眼查提供，由程序或算法识别中标信息页面生成，可能与实际存在差异，不作为决策依据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250719192004a6b3d95b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250719192004a6b3d95b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["159646","BK0239","688739"],"gpt_icon":0},{"id":"2551978071","title":"成大生物涨5.03%创近4个月新高 产品结构优化与估值修复预期驱动","url":"https://stock-news.laohu8.com/highlight/detail?id=2551978071","media":"智选洞察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551978071?lang=zh_cn&edition=full","pubTime":"2025-07-14 10:46","pubTimestamp":1752461200,"startTime":"0","endTime":"0","summary":"成大生物股价今日表现强势，截至10点46分，公司股价上涨5.03%，报27.98元/股，创近4个月以来新高。医药生物板块年内涨幅仅0.43%，弱于周期股表现，防御属性资产阶段性承压。公司狂犬疫苗收入占比超91%，产品集中度高叠加政策预期扰动，部分资金选择获利了结。技术壁垒与管线突破构筑价值锚点长期看，成大生物在狂犬疫苗领域的领先地位及全球化战略仍是核心支撑。机构普遍认为，公司现金流稳健，但短期估值修复需更多催化剂支撑。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714104648a6a7a43c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714104648a6a7a43c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688739"],"gpt_icon":0},{"id":"2549131827","title":"成大生物获得实用新型专利授权：“一种连续流超声破碎装置”","url":"https://stock-news.laohu8.com/highlight/detail?id=2549131827","media":"证券之星企业动态","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549131827?lang=zh_cn&edition=full","pubTime":"2025-07-05 02:43","pubTimestamp":1751654599,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示成大生物新获得一项实用新型专利授权，专利名为“一种连续流超声破碎装置”，专利申请号为CN202422030606.1，授权日为2025年6月20日。该装置使用简便，保证；超声过程密闭无菌，可进行大规模细胞破碎生产。今年以来成大生物新获得专利授权5个，较去年同期减少了80.77%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250705024654979a3b55&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250705024654979a3b55&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688739","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1758235580026,"stockEarnings":[{"period":"1week","weight":-0.022},{"period":"1month","weight":-0.0631},{"period":"3month","weight":0.0739},{"period":"6month","weight":0.0416},{"period":"1year","weight":0.2646},{"period":"ytd","weight":0.0861}],"compareEarnings":[{"period":"1week","weight":-0.0113},{"period":"1month","weight":0.028},{"period":"3month","weight":0.1404},{"period":"6month","weight":0.1387},{"period":"1year","weight":0.4101},{"period":"ytd","weight":0.1432}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"辽宁成大生物股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"25344人(较上一季度减少0.42%)","perCapita":"16431股","listingDate":"2021-10-28","address":"辽宁省沈阳市浑南区新放街1号","registeredCapital":"41645万元","survey":" 辽宁成大生物股份有限公司的主营业务是人用疫苗的研发、生产与销售。公司的主要产品是人用狂犬病疫苗和人用乙脑灭活疫苗。","listedPrice":110},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.3","shortVersion":"4.35.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"成大生物(688739)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供成大生物(688739)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"成大生物,688739,成大生物股票,成大生物股票老虎,成大生物股票老虎国际,成大生物行情,成大生物股票行情,成大生物股价,成大生物股市,成大生物股票价格,成大生物股票交易,成大生物股票购买,成大生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"成大生物(688739)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供成大生物(688739)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}